Publicacións en colaboración con investigadores/as de University Hospital of Zurich (32)

2020

  1. Prognostic assessment of valvular surgery in active infective endocarditis: Multicentric nationwide validation of a new score developed from a meta-analysis

    European Journal of Cardio-thoracic Surgery, Vol. 57, Núm. 4, pp. 724-731

2019

  1. SECTCV recommendations document in cardiovascular surgery. 2019 updating of the standards in organization, professional activity, quality of health-care, and training in the specialty

    Cirugia Cardiovascular, Vol. 26, Núm. 2, pp. 104-123

2016

  1. Infection-related and -unrelated malignancies, HIV and the aging population

    HIV Medicine, Vol. 17, Núm. 8, pp. 590-600

2015

  1. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

    HIV Medicine, Vol. 16, Núm. 9, pp. 533-543

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  3. Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 2, pp. 1282-1291

  4. ITPA genotypes predict anemia but do not affect virological response with interferon-free faldaprevir, deleobuvir, and ribavirin for HCV infection

    PLoS ONE, Vol. 10, Núm. 12

2014

  1. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

    Infection, Vol. 42, Núm. 4, pp. 757-762

  2. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study

    BMC Nephrology, Vol. 15, Núm. 1

  3. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe

    PLoS ONE, Vol. 9, Núm. 1

2013

  1. Faldaprevir and deleobuvir for HCV genotype 1 infection

    New England Journal of Medicine, Vol. 369, Núm. 7, pp. 630-639

  2. Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients

    PLoS ONE, Vol. 8, Núm. 5

  3. Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy

    HIV Medicine, Vol. 14, Núm. 6, pp. 370-378

2012

  1. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

    AIDS, Vol. 26, Núm. 15, pp. 1917-1926

  2. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: The EuroSIDA study

    PLoS ONE, Vol. 7, Núm. 7

2011

  1. A376s in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy

    Journal of Infectious Diseases, Vol. 204, Núm. 5, pp. 741-752

  2. European recommendations for the clinical use of HIV drug resistance testing: 2011 update

    AIDS Reviews, Vol. 13, Núm. 2, pp. 77-108

  3. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: The ARTEN Trial

    Antiviral Therapy, Vol. 16, Núm. 3, pp. 339-348

2010

  1. Dialysis and renal transplantation in HIV-infected patients: A European survey

    Journal of Acquired Immune Deficiency Syndromes, Vol. 55, Núm. 5, pp. 582-589

  2. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

    AIDS, Vol. 24, Núm. 11, pp. 1667-1678